Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Hypertriglyceridemia

ClinicalTrials.gov lists 329 trials for Hypertriglyceridemia or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 12.

MeSH D015228 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 36 Phase 1/2 Phase 1/2 9 Phase 2 Phase 2 64 Phase 2/3 Phase 2/3 8 Phase 3 Phase 3 54 Phase 4 Phase 4 34 Not applicable Not applicable 96 Observational Observational 26 Phase 1 Phase 1 36 Phase 1/2 Phase 1/2 9 Phase 2 Phase 2 64 Phase 2/3 Phase 2/3 8 Phase 3 Phase 3 54 Phase 4 Phase 4 34 Not applicable Not applicable 96 Observational Observational 26

Trials per phase

1 more section with rows

315 of the 329 trials are tagged with Hypertriglyceridemia itself; the rest are tagged with a narrower condition beneath it.

Get the Hypertriglyceridemia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Hypertriglyceridemia trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 20

1993: 1 trials (Observational 1) 1994: 1 trials (Observational 1) 1996: 1 trials (Observational 1) 1999: 1 trials (Phase 2 1) 2000: 1 trials (Observational 1) 2001: 5 trials (Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2002: 4 trials (Observational 1, Not applicable 2, Phase 3 1) 2003: 5 trials (Not applicable 2, Phase 3 1, Phase 2 2) 2004: 6 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 2) 2005: 8 trials (Not applicable 2, Phase 4 2, Phase 3 3, Phase 2 1) 2006: 11 trials (Not applicable 6, Phase 4 3, Phase 2 2) 2007: 11 trials (Not applicable 3, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1 1) 2008: 11 trials (Not applicable 4, Phase 3 1, Phase 2 5, Phase 1 1) 2009: 16 trials (Not applicable 1, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 1/2 2, Phase 1 1) 2010: 16 trials (Observational 5, Not applicable 2, Phase 4 2, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2011: 20 trials (Not applicable 3, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1 4) 2012: 18 trials (Not applicable 7, Phase 4 4, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1 1) 2013: 14 trials (Not applicable 6, Phase 3 1, Phase 2 6, Phase 1 1) 2014: 16 trials (Observational 4, Not applicable 3, Phase 4 1, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 3) 2015: 11 trials (Not applicable 2, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 1) 2016: 14 trials (Observational 1, Not applicable 5, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1 2) 2017: 9 trials (Not applicable 2, Phase 4 3, Phase 2 3, Phase 1/2 1) 2018: 13 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 2) 2019: 14 trials (Observational 1, Not applicable 11, Phase 1 2) 2020: 13 trials (Observational 1, Not applicable 4, Phase 4 1, Phase 3 2, Phase 2 3, Phase 1 2) 2021: 11 trials (Not applicable 4, Phase 3 4, Phase 2 2, Phase 1 1) 2022: 12 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2 2, Phase 1 1) 2023: 9 trials (Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 2024: 20 trials (Observational 2, Not applicable 7, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 3) 2025: 13 trials (Observational 1, Not applicable 3, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 18
2025 13
2024 20
2023 9
2022 12
2021 11
2020 13
2019 14
2018 13
2017 9

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 20 trials starting in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 26 months from start to primary completion across 27 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 232 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Hypertriglyceridemia trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 36
Phase 1/2 9
Phase 2 64
Phase 2/3 8
Phase 3 54
Phase 4 34
Not applicable 96
Observational 26
Expanded access 2

How many Hypertriglyceridemia trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 12
Recruiting 21
Enrolling by invitation 1
Active, not recruiting 15
Completed 224

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Hypertriglyceridemia trials? (13)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
AstraZeneca 12
Ionis Pharmaceuticals, Inc. 10
Arrowhead Pharmaceuticals 8
GlaxoSmithKline 7
Essentialis, Inc. 6

Showing 5 of 13 sponsors.

Start your 14-day trial Email me all 13 sponsors as a PDF

Which drugs are being tested for Hypertriglyceridemia? (11)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
LOVAZA 15
Icosapent Ethyl 6
Olezarsen 6
Metreleptin 6
ATORVASTATIN 5

Showing 5 of 11 drugs.

Start your 14-day trial Email me all 11 drugs as a PDF

Interventions as named in the registry (4)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 19
ER Niacin 4
CaPre 4
DR10624 Injection 4

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Hypertriglyceridemia trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 232 7
Osteoarthritis 158 3
Chest pain 133 2
Non-cardiac chest pain 110 7
Angina pectoris 103 6

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Hypertriglyceridemia? (348)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. The New England journal of medicine 2026 Yes
Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia. American heart journal 2025 Yes
Global burden and characterization of hypertriglyceridemia-induced acute pancreatitis: results from a systematic review and a multi-center cohort study. Science China. Life sciences 2025 Yes
Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes. Med (New York, N.Y.) 2025 Yes
Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia-A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study. Journal of atherosclerosis and thrombosis 2025 Yes

Showing 5 of 348 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages